| Name | Title | Contact Details |
|---|
Pinetree Therapeutics is an award-winning, pre-clinical stage biotechnology company based in Cambridge, Massachusetts. We are dedicated to finding solutions for unmet medical need, such as drug resistance and tumor recurrence, in targeted therapy by degradation of disease-causing proteins with AbReptorTM platform. Novel degrader drugs have been exciting scientific field, due to its distinct mechanism of action (removal of disease-causing protein). AbReptorTM was developed for targeted degradation on membrane bound and extracellular proteins causing diseases. Receptor tyrosine kinase (RTK) and non-RTK inhibitors have made huge progress in the past few years, but their application is limited due to specificity, drug resistance, and on-target toxicity. Our platform`s RTK degraders promise to redefine their distinctive mutation-agnostic properties, differing from existing RTK therapeutics field. With the pre-clinical animal study, our lead molecule demonstrated on-target degradation, mutation agnostic anti-tumor effect, and potent anti-tumor effect in RTK inhibitor resistant tumor. Surprisingly, no signs of toxicity were found in rodent and cynomolgus monkey. Furthermore, it would unluck full potential to solve limitation of RTK and non-RTK therapeutics. Immune checkpoint inhibitors (ICIs) field made an initial breakthrough with poor response rate, high toxicity profiles, and exhausted poor clinical outcome. Our platform has full potential to solve the current problem of immune checkpoint inhibitors (ICIs), PD-(L)1 inhibitors. Our PD-(L)1 degrader is the first ever in-class to demonstrate enhanced anti-tumor immunity in pre-clinical animal studies. Pinetree Therapeutics` lead molecule is in pre-clinical IND stage, and we are committed to expanding our platforms to other target proteins, such as RTKs, non-RTKs, and ICIs. We believe our platform has the potential to transform the field of medicine and revolutionize the treatment of cancer and other diseases.
OncoArendi Therapeutics SA (WSE:OAT) is a Polish innovative biotechnology company specializing in research, development and commercialization of innovative small molecule drugs for treatment of respiratory diseases and cancer.
Abzena is a life science group with headquarters in the UK, and chemistry and manufacturing sites in the US. Abzena`s complimentary services and technologies in chemistry, biology and manufacturing, are applied to the selection, development and manufacture of better biopharmaceuticals. Abzena works with most of the top 20 biopharmaceutical companies and academic groups around the world, and has enabled many of them to progress products (ABZENA inside), through to clinical development. Abzena`s teams at the Babraham Research Campus, Cambridge, UK, in San Diego, CA and Bristol, PA in the US are focused on developing better treatments for patients.
Medcura, Inc. has developed an advanced wound care platform that can be used across a broad spectrum of clinical and non-clinical settings. By making molecular modifications to natural biopolymers, Medcura`s patented approach provides rapid hemostasis in a clean, safe healing environment. The company has achieved milestones such as 3 FDA Clearances, 6 issued patents, and 7 peer-reviewed publications.
Retrophin is a biopharmaceutical company focused on the discovery, acquisition, development and commercialization of drugs for the treatment of debilitating and often life-threatening diseases for which there are currently limited patient options.